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Objective of the thesis
Article-27.1 of the TRIPs agreement
Patents shall be available for any inventions, whether products or processes, in all fields of 
technology, provided that they are new, involve an inventive step and are capable of  industrial 
application. patents shall be available and patent rights enjoyable without discrimination as to the place 
of invention, the field of technology and whether products are imported or locally produced.
 Article 7: Protection and enforcement of Intellectual Property Rights should contribute to the 
promotion of Technological innovation and transfer and dissemination of technology to the mutual 
advantage of producer and user of the technological knowledge, in a manner conducive to social 
and economic welfare and balance of rights and obligations.
So the relationship of two very Articles (Article 7 and 27) in the context of Indian biopharma 
Industry to know the impact of TRIPs agreement on developing country like India. 
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Background 
Why biopharma technology is needed for India?
1. Advances in the recombinant DNA technology, study of the cell growth, gene therapy 
proteomics, and bioinformatics contribute to the development of proteins can provide 
cures for many chronicle and hereditary disease as Alzheimer disease HIV AIDs, Malaria 
tuberculosis.
2. important for a country like India where there is widespread of these diseases.  
3. investment for these drugs innovations is negligible, therefore availability through 
technology transfer from the multinational innovator companies are 
desired.
Such necessary technology needs to be developed by putting more and more investment into R&D 
and transferred to developing countries to reduce the spread and impact of disease which improves 
socio economic standing of the improvised populations.
If the potential is so great of biotechnology research, then what is all the opposition and controversy 
for? 
patenting of DNA sequence is related with the blueprint of life.
- several moral and ethical issues are attached with the patenting of the same. 
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Indian biopharmaceutical industry: Where does it stands 
in Globe?
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Methodology used for the thesis
Industry level data 
 Firm level data
 Interview data- 45 Indian biopharmaceutical CEO, 10 MNC 
biopharmaceutical CEOs based in India,
 10 NGOs working on public health in India, 5 states biotech 
department secretaries, Director General of CSIR, Science and 
technology Minister, Government of India.
Scrutinizing legal text 
 TRIPs agreement text
 Doha Declaration 
 30th Aug
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1991 1993 1995 1997 1999 2001 2003 2005
year
Foreign technology transfer in Indian biopharma sector
Number of Financial (FDI)cases approved in Biopharmaceutical sector
Number of Technical (Technology collaborations, licensing and joint ventures) cases approved in
Biopharmaceutical sector
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Comparative importance of factors considered in decision 
making for the transfer of technology in Indian bipharma 



















































































After the introduction of product patents in India has enhanced the innovator’s
incentive to innovate but still multinational biopharmaceutical companies demands-
higher patent standards and data exclusivity etc
On the demand of the MNCs there are there are three issue which have been
Raised:
1. Access to drugs- Higher price
2. Moral and ethical issue due to higher life form patenting
3. Access to genetic resource
4. Death knell for domestic generic industry
Aim of the presentation
Suggest optimal policy (Patent and other regulations) to have a balance between 
biopharma drugs innovation and their access in India while complying with the 
provisions of the TRIPs agreement. 
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Optimal policy design 
Optimal policy for India








Indian position on higher life form patenting
"higher life form
 not defined in law. 
In common usage
plants and nonhuman animals other than single-celled organisms. 
India: Current position
The landmark judgment of Dimminiaco AG vs. Controller of patents (2001) Kolkata high court 
held  the biotech matter as patentable even if the end product of a process is a living virus/microorganism / 
living entity. 
Section 3 of the Patent Amendment Act 2002
excluded from patentability, plants, animals in whole or any part thereof other than microorganisms 
but includes seeds varieties of seeds varieties species and essentially biological processes for 
production or propagation of plants and animals. 
 Patent amendment Act 2005 has  accepted living entities of artificial origin such as microorganism and 
vaccines which fulfills the cardinal principle of patentability and not harmful to human, animal or plant 
health or unethical.
 controversy : Current controversy:
Presently there is controversy with regard to the definition of microorganisms as there is absence of a 
working definition of microorganism in the TRIPs text.
Question
whether India should adopt a very narrow and limited definition of microorganism to exclude 
everything other than microscopic organisms including algae, bacteria, fungi, protozoa and viruses or 
whether it should expand the scope as in the Europe where all biological material containing genetic 
information and capable of reproducing itself or being reproduced in a biological system?
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TRIPs Requirement: Art 27(3)- Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals; 
(b) plants and animals other than micro-organisms, and essentially biological processes for the 
production of plants or animals other than non-biological and microbiological processes. 
US practice - Diamond Vs Chakrabarty,United States Supreme Court, June 16, 1980,    
447 U.S. 303, 206 USPQ 193
- isolated and purified gene sequences are awarded patent              
protection in accordance with the novelty standard as per USC 102
- utility requirement under 35 USC 101 
- for ascertaining the obviousness of an invention  - Duel case
re Thomas F. DEUEL; No. 94-1202; March 28, 1995; USFDA
EU practice:
Article 4 of the Biotech Directive (98/44/EC) animals and plant variety is not permitted for patenting
but Article 4.2 -
- Article 5 of EC directive (98/44/EC) 
- Biogen vs. Medeva, 1997; RPC; 1
- The European Directive on Biotechnological Inventions (No. 96/9/EC of March 11, 1996) 
- European Directive (98/44/EC) provides broader definition of "Biological material" 
- Directive 98/44/EC – moral doctrine
- Article 6 of the EPC 
- Article 53(a) of the EPC prohibits patents for inventions that are contrary to the morals of society.
- Harvard oncomouse case – US 
- Florey/relaxin case 1995; O.J.E.P.O, 388
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 Higher life form patenting: benefits for India
 financial incentive to industry to invent, 
 Away from international patenting standard
 Important for newer innovation in field of biotechnology
 Problem related with the higher life form patenting
 broader scope of biotech patentability currently, there are two problems:
 Access to basic platform technology such as DNA sequences, cell lines, 
plants and animals at reasonable costs which are crucial to the research. 
 patents on plants and animals or any biological material (DNA sequences, 
genes, cells) – not ethical and moral.
Recommendation: Human Beings Not Patentable - however, prevent 
patent claims from being granted with respect to DNA sequences, cell lines or 
stem cells of human origin. 
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Balancing Act
Laws such as the Competition Act, the Criminal Code, prohibit certain types of 
behaviour such as unfair economic practices, cruelty to animals, or the cloning 
of human beings.
before many products can be sold in India, compliance with regulations 
designed to protect human and environmental health, to ensure product safety 
and to meet other requirements. Compliance with voluntary standards, such as 
Good Laboratory Practices is necessary to maintain public confidence in the 
product and its maker. 
social and ethical considerations raised specifically by biotechnology should 
continue to be addressed primarily outside the Patent Act. 
Access to Genetic material: Bolar provision
20
Controversy:
Novartis AG in 2007 filed writ petition challenging Section 3 (d) 
denies Article 27 of the TRIPS Agreement, which obligates WTO member states to provide 
patent protection to all fields of technology without discrimination. 
in the absence of a definition or guideline, phrases like ‘enhancement of the known efficacy' or 
‘differ significantly in properties with regard to efficacy' give  uncontrolled as well as unguided 
powers to the Controller of  Patents. 
violates the right to equality under Article 14 of the Constitution of India.
§3(d))- ‘The mere discovery of a new form of a known substance which does 
not result in the enhancement of the known efficacy of that substance or the 
mere discovery of any new property or new use for a known substance or the 
mere use of a known process, machine or apparatus unless such known 
process results in a new product or employs at least one new reactant.
‘ Salts, esters, ethers, polymorphs, metabolites, pure form, particle size,
isomers, mixtures of isomers, complexes, combinations and other derivatives 
of known substance shall be considered to be the same substance, unless 
they differ significantly in properties with regard to efficacy.'
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Argument of the other interest group:- 1 Ever greening, 2 frivolous patents, 3. 
generic drugs adversely affected, 4. prices will be high.
Decision
- Rejected Glivec patent application on the ground that a patent  cannot be 
granted for “the mere discovery of a new form of a known substance which 
does not result in the enhancement of the known efficacy of that substance.”
Analysis
Difference between incremental innovation and ever greening
Benefit of incremental innovation for India
- improving therapeutic efficacy, but also in providing significant 
benefits in terms of drug delivery, patient safety and compliance 
- Newer drugs innovation to combat diseases
- More foreign investment
Recommendation
Patents on Salts, esters, ethers, polymorphs, metabolites, pure form, particle 
size, isomers, mixtures of isomers, complexes, combinations and other 




Optimal Patent length for India
 The length of the patent protection characterizes the duration of monopoly power.
 Controversy:
MNC- Data Exclusivity- Article 39.3 of TRIPs text and Indian Patent Act 2005, advocating a 
definition to mean a new pharma product which has been introduced for the first time in a 
country irrespective of the fact whether it is patented or not. Another controversial matter is that 
what constitutes ‘unfair commercial use’ under Article 39.3.
Health Advocates and scholars: 
- death knell for the Indian biopharma industry,
- Prices of t he drugs will be high
Data-
Data exclusivity-
Data protection and data exclusivity-
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Article 39.3 of the TRIPS Agreement:
Members when requiring as a condition of approving marketing of  pharmaceutical or of 
agricultural chemical product which utilize new chemical entities, the submission of 
undisclosed test or other data, the originator of which involves considerable efforts shall 
protect such data against disclosure, expect where necessary to protect the public or unless 
steps are taken to ensure that the data are protected  against unfair commercial use“
Article 39.1 provides- In the course of ensuring effective protection against unfair 
competition as provided in Article 10bis of the Paris Convention (1967), Members shall 
protect undisclosed information in accordance with paragraph 2 below with data submitted 
to governments or governmental agencies in accordance with paragraph below. 
 Article 10bis of the Paris Convention: 
 Article 6 of the WIPO model: Any act or practice, in the course of industrial or 
commercial activities, that results in the disclosure, acquisition or use by others of secret 
information without the consent of the person lawfully in control of that information 
(hereinafter referred to as "the rightful holder") and in a manner contrary to honest 
commercial practices shall constitute an act of unfair competition.
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- Satwant Reddy Committee constituted by Government of India 
has also recognized that not providing data exclusivity for 
pharmaceuticals could adversely impact FDI and discourage the 
launch of new products in India.
Recommendation
Five years of data exclusivity either starting from the date on 
which the company markets its product or ending with the expiry 
of patents whichever is earlier provided that company must have 
filed a patent in India.
Reason
- India has a well-developed Pharmaceutical industry, 




balance between access and innovation














 Indian Patent Act 2005-
 Experience in India
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Thailand and CL
In January 2007, compulsory license for Kaletra 
Patented by Abott, and Plavix patented by Sanofi 
Aventis.
Abott laboratories cut the price of second line drug 
lopinavir / ritanivir, to $ 1,000 /month from $ 2, 200 / 
Month for 45 lower and middle income countries.
Merck immediately cut the price of first line 




Threat of compulsory license pressured 
pharmaceuticals trail companies like Abott Merck and 
Roche manufacturer of Lopinavir, indinavir, melfinavir 
and saquinavir respectively) to substantially reduce the 
price, thus enabling 100,000 people to receive free 
treatment. 
whether the same thing can happen in India? 
- Hoffman La Roche Ltd Vs. Cipla ltd
- Novartis case (the famous glivec case)
On the other hand at the same time, the drug 
companies worry that countries will abuse compulsory 
business, 
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 Optimal patent policy for India 
The arguments 
in India the combined taxes and tariffs on imported medicines are 55 
percent.(Wilson Tim, 2008) To control the drugs prices, there is proper drug 
price control mechanism of Drug Price Control Order (DPCO). 
compulsory licensing undermine IP in case of national emergency or other 
circumstances of extreme urgency or in case of public non commercial use. As 
there is need to balance between innovation and access.
 Suggestion
Broader with higher life form patentability, incremental innovation and 5 years 
of data exclusivity with a balanced flexibility provisions and implementation of 
compulsory license mechanism, other regulatory and fiscal policies.
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Part 2 optimal Regulatory policy for 
India
Regulatory policy for India
Drug Regulations Fiscal Policy
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 Factors 
According to the report of the Investment Commission 2006, the major impediments to 
investment have been identified as 
 investment restrictions and/ or entry route barriers, 
 absence of long-term policies, 
 inflexible labour laws,
 bureaucratic delays, 
 discretionary interpretation, 
 vested interest, bias and subjective practices,
 high cost of entry, transactions and exit; ineffective dispute resolution,
 poor infrastructure. 
These impediments can be categorized in two groups, tariff barriers and non tariff 
barriers. 
Tariff Barriers : higher rate of taxation, royalty, interest, gains from sale of capital assets 
located in India higher fees for technical services etc.
Non-tariff barriers : attitudes and bias toward foreign products, a rigid distribution system, 
and Government bureaucracy. 
Access to drugs are affected : pricing policy, pharmaceutical procurement policy, 
Government subsidy policy, drug distribution policy, Administrative efficiency.
 - We find some common factors which can influence both investment and access such as 
pricing policy which needs careful framework to balance both
 - On the other hand there are factors which individually affect each proper framework of 
the same can balance the negative generated by the policy which affect both in common
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Government initiative in framing regulations:
Establish Central Drug regulatory authority (CDA) with a single, central, 
FDA-style agency.
- All facility-inspection, manufacturing-license, and data-evaluation  
functions concerning drugs in India. 
- Separate, semi-autonomous Departments for regulation, enforcement, 
legal, and consumer affairs; biotechnology products; pharmacovigilance 
and drugs safety; medical devices and diagnostics; imports; quality 
control; and traditional Indian medicines. It will set up offices throughout 
India for inspection, registration, and license.
 biotech Parks promotion policies: The DBT - 10 biotech parks by 2010. 
- In the biotech parks, concession like tax holiday U/S 10B of Income Tax 
Act 1961, duty free or import of equipments, instruments etc.
 The National biotechnology strategy 2007 provides many fiscal and non 
fiscal benefits to the industry. 
- 100 percent FDI approved in biotech
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 Government initiative to procure access 
The Drug Policy Control Order 2006 declared that bulk drugs developed 
by Indian companies would be exempt from price control for five years 
or, in the case of new drugs, 10 years. Goods developed in India and 
patented in the U.S., Japan or E.U. enjoy a three-year waiver from 
excise duty, and companies get a 10-year tax holidays for income 
stemming from qualifying R&D.




An 8 percent reduction in export duties along with export duties 
exemption for indigenous life saving drugs and 5 percent customs duty 
reduction for imported life saving drugs by the budget of 2008-09 will 
definitely make the drugs price lower. In fact this is a better way to 
address drugs costs rather than drugs price control. Given the current 
international political climate, systemic, Government driven reform of 
intellectual property protection seems unlikely in the near term. 
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Suggestion and Conclusion
optimal design of patent for biopharma innovation in India 
should confine to trade off between patent length and breadth 
taking into account the flexibility provisions of TRIPs. Larger 
breadth makes it more difficult to imitate, whereas increasing 
the duration of patent protection enhances the incentives to 
improve the invention by increasing R&D investment for the 
innovation of biopharmaceutical drugs in general and neglected 
diseases drugs through foreign investment in particular carrot in 
terms of data exclusivity and higher form of patent protection 
should be given along with the stick of properly framed 
compulsory licensing provision and parallel importation to 
balance the need of the access. Government subsides promote 
the development of biopharma technologies. 
